|
|
Upfront Briefing
GSK’s $950M takeout of 35Pharma is the clearest signal today: strategic buyers are still willing to pay real cash for earlier-stage, mechanism-led assets when the biology fits a long-term franchise build.
Elsewhere, Novo Nordisk’s planned 2027 Wegovy list-price cut reinforces that GLP-1 pricing pressure is structural, while non-dilutive capital keeps flowing via Ethris’ EU-backed pandemic flu contract.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,890.1 |
+0.8% |
+0.7% |
| Nasdaq 100 |
24,977.0 |
+1.1% |
(1.1%) |
| Russell 2000 |
2,652.3 |
+1.2% |
+6.9% |
| Healthcare (XLV) |
157.9 |
(0.4%) |
+2.0% |
| Biotech (XBI) |
129.2 |
+1.7% |
+5.9% |
| Nasdaq Biotech (NBI) |
6,061.8 |
+0.8% |
+6.2% |
| Clinical Trials (BBC) |
42.6 |
+3.1% |
+10.6% |
|
- Risk appetite improved across U.S. equities on Tuesday: the S&P 500 and Russell 2000 rebounded, while the Nasdaq 100 pushed back toward highs after a softer start to the week.
- Healthcare lagged even as risk returned: XLV fell on the day, suggesting large-cap defensives/pharma were less in favor, while XBI and BBC outperformed as investors rotated back into higher-beta biotech.
- Takeaway for biotech: the tape remains selective, but M&A/deal flow and idiosyncratic catalysts are still driving better relative action in smid-cap biotech than in broader healthcare.
The Big 3
|
1
|
GSK to acquire 35Pharma for $950M cash
|
- GSK agreed to acquire Canada’s 35Pharma for $950M in cash, adding HS235, an early-stage pulmonary hypertension asset, as CEO Luke Miels continues to rebuild pipeline ahead of looming HIV patent expiries.
- Why it matters: This is another signal that strategics are willing to pay meaningful cash for earlier, science-led assets if the mechanism can support a multi-indication platform. For investors, it reinforces that “M&A bid support” is moving further left again — not just pre-commercial assets, but earlier-stage programs with strong biological rationale and franchise fit.
- Source: Reuters
- More: FT
|
|
2
|
Novo Nordisk to cut Wegovy list price in 2027
|
- Novo Nordisk plans to reduce the list price of its GLP-1 drug Wegovy by half in 2027, signaling increasing price pressure in the obesity market.
- Why it matters: This is less about an immediate “price war” and more about confirming that GLP-1 list prices are heading lower as Medicare negotiation, payer pressure and competitive intensity reshape the gross-to-net. For investors, that matters because long-term obesity models increasingly need to underwrite lower headline pricing, even if net realized pricing and cash-pay channels remain more resilient near term.
- Source: Reuters
- More: Endpoints
|
| 3 | Ethris consortium wins EU pandemic flu vaccine contract |
- An Ethris-led consortium was selected for a European Commission pandemic influenza vaccine contract worth up to EUR 148 million, with an initial EUR 13 million phase and later gated competitive stages.
- Why it matters: The important signal here is not just the headline “up to” value, but third-party, non-dilutive validation of the platform. If the consortium advances through later stages, this can extend runway, fund development and strengthen future partnering leverage without issuing equity.
- Source: PR
|
Everything Else that broke
- Werewolf Therapeutics to explore strategic alternatives. — PR
- Vaxcyte reports Q4/FY2025 results, VAX-31 Phase 3 underway. — PR
- HHS commits up to $144M via ARPA-H for anti-aging study. — Endpoints
- Gossamer, Grail shares fall after late-stage misses. — BioCentury
- Serina Therapeutics doses first patient in SER-252 trial. — PR
- Cardiff Oncology FY2025 results, Phase 2 CRDF-004 update. — PR
- Novo's 'triple G' shows competitive weight loss in Phase II. — BioCentury
- Basilea receives $6M BARDA funding for antibiotic. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly
⬇️
|
M&A / BD&L
- GSK to acquire 35Pharma for $950M cash, adding early-stage pulmonary hypertension program HS235. — Reuters
- Junshi Biosciences and Antengene announced a clinical collaboration to evaluate JS207 in combination with ATG-037. — PR
- SteinCares and Shilpa Biologicals ink a biosimilars licensing deal to expand access across Latin America. — PR
VC / Private Financings
- Turbine: $25M Series B — led by Interactive Venture Partners; joined by Beiersdorf Venture Capital, MSD Global Health Innovation, Accel and Mercia. — PR
- Brainomix: Series C extension to $25.4M (£18.8M) — led by Parkwalk and Hostplus via the IP Group Hostplus Innovation Fund; joined by Modi Ventures. — PR
- Ethris-led consortium selected for a European Commission contract worth up to EUR 148M (initial EUR 13M phase) for a pandemic influenza vaccine. — PR
- Basilea receives an additional $6M in BARDA funding for antibiotic development. — PR
IPOs / Follow-Ons
- No notable biotech IPO or follow-on announcements since yesterday.
|
|
That’s it for today — mind the list price, and read the fine print. See you tomorrow. BioBucks Team
|
|
|
